Phase 3Recruiting
A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome (SLORP Preserve)
A 24-Month, Randomized, Double-Masked, Placebo-Controlled Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis PigmentosaAssociated With Usher Syndrome
- Sponsor
- Nacuity Pharmaceuticals, Inc. (Industry)
- Enrolment
- 80 planned
- Conditions
- Retinitis Pigmentosa (RP); Usher Syndrome
- Interventions
- Placebo; NPI-001
- Ages
- adults, older adults
- Registry
- NCT07710196
Full record on ClinicalTrials.gov
From the registry
The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are: Does NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision. Participants will: Take NPI-001 or a placebo twice a day, every day for 24 months and visit the clinic 9 times for checkups and tests.
Primary outcomes
- Ellipsoid Zone Area
History
Primary completion expected
Started
Last registry update
Registered